(Q34277837)

1 August 2017

1 reference

title

Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis (English)

1 reference

1 August 2017

0 references

0 references

1 reference

Matheson AJ

1

1 reference

1 August 2017

Figgitt DP

series ordinal

2

1 reference

1 August 2017

publication date

1 January 2001

1 reference

1 August 2017

1 reference

1 August 2017

volume

61

1 reference

1 August 2017

issue

6

1 reference

1 August 2017

page(s)

833-865

1 reference

1 August 2017

cites work

Primary dysmenorrhoea

1 reference

12 December 2020

Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain

1 reference

12 December 2020

Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles

1 reference

12 December 2020

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

1 reference

12 December 2020

Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group

1 reference

12 December 2020

RETRACTED: Postoperative analgesic effects of celecoxib or rofecoxib after spinal fusion surgery

1 reference

12 December 2020

COX-1-sparing NSAIDs--is the enthusiasm justified?

1 reference

12 December 2020

Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans.

1 reference

12 December 2020

Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: a randomized, placebo- and active-comparator-controlled clinical trial

1 reference

12 December 2020

Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers

1 reference

12 December 2020

The increasing impact of arthritis on public health

1 reference

12 December 2020

A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group

1 reference

12 December 2020

Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen

1 reference

12 December 2020

EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT)

1 reference

12 December 2020

A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis

1 reference

12 December 2020

Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans

1 reference

12 December 2020

Mechanism of action of antiinflammatory drugs

1 reference

12 December 2020

Five studies on ibuprofen for postsurgical dental pain

1 reference

12 December 2020

Tolerability profiles of rofecoxib (Vioxx) and Arthrotec. A comparison of six weeks treatment in patients with osteoarthritis

1 reference

12 December 2020

A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group

1 reference

12 December 2020

1 reference

12 December 2020

Guidelines for the management of rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines

1 reference

12 December 2020

Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: a randomized controlled trial

1 reference

12 December 2020

COX-2 selective nonsteroidal anti-Inflammatory drugs: do they really offer any advantages?

1 reference

12 December 2020

The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group

1 reference

12 December 2020

Selective cyclooxygenase-2 inhibitors

1 reference

12 December 2020

A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers

1 reference

12 December 2020

Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protoco

1 reference

12 December 2020

Cyclooxygenase-2 selective inhibitors

1 reference

12 December 2020

Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States

1 reference

12 December 2020

Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model

1 reference

12 December 2020

Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Osteoarthritis Studies Group

1 reference

12 December 2020

Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs

1 reference

12 December 2020

COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin

1 reference

12 December 2020

A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects

1 reference

12 December 2020

Arthritis and the aging population: projections of arthritis prevalence in Canada 1991 to 2031.

1 reference

12 December 2020

1 reference

12 December 2020

Effect of rofecoxib on the pharmacokinetics of digoxin in healthy volunteers

1 reference

12 December 2020

Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis.

1 reference

12 December 2020

The cyclooxygenase-2 inhibitors: safety and effectiveness

1 reference

12 December 2020

Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines

1 reference

12 December 2020

Are the biologic and clinical effects of the COX-2-specific inhibitors an advance compared with the effects of traditional NSAIDs?

1 reference

12 December 2020

Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy M

1 reference

12 December 2020

Cyclooxygenase 2 selective inhibitors: panacea or flash in the pan?

1 reference

12 December 2020

Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production

1 reference

12 December 2020

Scientific rationale for specific inhibition of COX-2

1 reference

12 December 2020

Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: a randomized, controlled trial

1 reference

12 December 2020

Efficacy of single-dose and multidose rofecoxib in the treatment of post-orthopedic surgery pain.

1 reference

12 December 2020

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

1 reference

12 December 2020

Guidelines for the medical management of osteoarthritis

1 reference

12 December 2020

From prostaglandin replacement to specific COX-2 inhibition: a critical appraisal

1 reference

12 December 2020

10.2165/00003495-200161060-00019

Identifiers

DOI

1 reference

Dimensions Publication ID

1 August 2017

1018737577

0 references

1 reference